miR-181b, as a regulator of NF-κB signaling via importin-β3, emerges as a potential therapeutic target. miR-125b and miR-155 could serve as biomarkers for distinguishing CRS subtypes, while miR-92a and miR-26b are associated with decreased inflammation. The gene discussed is NFKB1; the disease is congenital rubella syndrome.